RUNX2 and acute myeloid leukemia: Although ARC knockdown sensitizes AML cells to chemotherapeutic agents [28], it neither altered AML cell viability nor markedly decreased cell growth (Figure 1C right panel), suggesting that decreased association of ARC KD OCI-AML3 cells to MSCs resulted from a decreased adhesion property in these cells.